BioInfra Co

BioInfra Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of BioInfra Co (199730.KQ) as of Nov 12, 2026 is 510.50 M KRW. In the previous year, Stock-Based Compensation (SBC) was 816.80 M KRW — a change of -37.50% (lower).

Stock-Based Compensation

510.50 MKRW

YoY

-37.50%

Last updated:

Stock-Based Compensation (SBC) of BioInfra Co is 2023 510.50 M KRW. Stock-Based Compensation (SBC) of BioInfra Co was 2022 816.80 M KRW. It decreases by -37.50% lower compared to the previous year.

The BioInfra Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
306.30 M KRW
Jan 1, 2022
816.80 M KRW
Jan 1, 2023
510.50 M KRW
The BioInfra Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
510.50 MKRW-37.50%
816.80 MKRW+166.67%
306.30 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioInfra Co Stock analysis

What does BioInfra Co do? BioInfra Co Ltd, based in Yongin, South Korea, operates in the Health Care sector, specifically within Life Sciences Tools & Services. The company focuses on research and development of medicines, chemical substances, and medical devices, alongside conducting drug development, non-clinical and clinical trials, and producing health functional foods. Listed on March 2, 2023, BioInfra employs 113 full-time staff. BioInfra Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioInfra Co stock

Stock-Based Compensation (SBC) of BioInfra Co is 510.50 M KRW in 2023.

Stock-Based Compensation (SBC) of BioInfra Co changed from 816.80 M KRW to 510.50 M KRW, representing a -37.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioInfra Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioInfra Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BioInfra Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BioInfra Co